MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.msard.2025.106691

Медицинская библиотека · Multiple sclerosis and related disorders · 2025

Risk stratification for disease reactivation after therapy de-escalation/discontinuation in relapsing multiple sclerosis by the VIAADISC score.

Bsteh Gabriel, Introcaso Vincenzo, Gradl Christiane, Traxler Gerhard, Barket Robert, Föttinger Fabian, Hammer Helly Noemi, Krajnc Nik, Ponleitner Markus, Zrzavy Tobias, Deisenhammer Florian, Pauli Franziska Di, Chan Andrew, Berger Thomas, Hoepner Robert, Hegen Harald

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

To investigate whether the VIAADISC score predicts disease reactivation in relapsing multiple sclerosis (RMS) after de-escalation/discontinuation of disease-modifying-therapy (DMT)

METHODS

We included RMS patients who i) received any DMT other than interferon-beta or glatiramer-acetate ≥12 months, ii) de-escalated/discontinued DMT, iii) had MRI before de-escalation/discontinuation, and iv) had ≥12 months of follow-up. VIAADISC score (0-6; age <45/45-54/≥55 = 2/1/0 points, MRI activity = 2 points, duration without clinical disease activity <4/4-8/>8 years = 2/1/0 points) was calculated. The primary endpoint was disease reactivation (relapse and/or disability progression).

RESULTS

Of 129 RMS patients included (65.1 % females), 44.2 % had received natalizumab (NTZ), 19.4 % dimethylfumarate (DMF), 17.1 % teriflunomide (TERI), 14.0 % fingolimod (FTY) and 5.4 % rituximab (RTX). At de-escalation/discontinuation, mean age was 44.3 years (12.3), median duration of clinical stability 2.4 years (IQR1.5-3.9) and 93.1 % were without MRI activity, resulting in median VIAADISC score of 3 (IQR 2-4). Over median 6.0 years, disease reactivation reoccurred in 55.0 %, most frequently after NTZ/FTY discontinuation (73.3 %). In Cox regression, risk of disease reactivation was independently predicted by higher VIAADISC scores (HR 1.25 per point [95 % CI 1.03-1.53], p = 0.028) and de-escalation from FTY/NTZ (HR 2.20 [CI 1.18-4.10], p = 0.013). No disease reactivation was observed when DMF/TERI were discontinued with VIAADISC <2.

INTERPRETATION: Risk of disease reactivation after discontinuation from DMF/TERI can be stratified with the VIAADISC score and appears to be safe above age 45-55 and with long-lasting stability. However, risk after de-escalation from NTZ/FTY is too high to allow reliable stratification and should be avoided by lateral switch.

Для цитирования: Bsteh Gabriel, Introcaso Vincenzo, Gradl Christiane, Traxler Gerhard, Barket Robert, Föttinger Fabian, Hammer Helly Noemi, Krajnc Nik, Ponleitner Markus, Zrzavy Tobias, Deisenhammer Florian, Pauli Franziska Di, Chan Andrew, Berger Thomas, Hoepner Robert, Hegen Harald. Risk stratification for disease reactivation after therapy de-escalation/discontinuation in relapsing multiple sclerosis by the VIAADISC score.. Multiple sclerosis and related disorders. 2025. DOI: 10.1016/j.msard.2025.106691.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.